Sanofi-Aventis S.A. ADR (NQ: SNY )

57.65 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist

Price and Volume

Volume	2,751
Open	57.65
Bid (Size)	57.66 (10)
Ask (Size)	57.70 (10)
Prev. Close	57.65
Today's Range	57.65 - 57.65
52wk Range	42.63 - 58.97
Shares Outstanding	1,250,690,553
Dividend Yield	3.30%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Week In Review: Zenas Raises $259 Million In IPO

September 28, 2024

It was a quiet week for biotech news in the Chinese market. Here is a brief overview of the notable events that occurred during this time. Zenas BioPharma staged a rare US biopharma IPO worth $259...

Via Talk Markets

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

September 27, 2024

The FDA approved Regeneron and Sanofi's Dupixent as an add-on treatment for inadequately controlled COPD, demonstrating significant reductions in exacerbations and improved lung function in Phase 3...

Via Benzinga

Performance

YTD	+15.30%	+15.30%
1 Month	+2.47%	+2.47%
3 Month	+16.32%	+16.32%
6 Month	+19.38%	+19.38%
1 Year	+7.60%	+7.60%

More News

Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent

September 27, 2024

Via Investor's Business Daily

Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)

September 27, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

September 25, 2024

Via Benzinga

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

September 25, 2024

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

September 25, 2024

Via Benzinga

Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

September 24, 2024

Via MarketBeat

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

September 23, 2024

Via Benzinga

Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval

September 23, 2024

Via Benzinga

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

September 20, 2024

Via Benzinga

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

September 20, 2024

Via Benzinga

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

September 20, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years

September 18, 2024

Via Benzinga

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

September 13, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Time To Invest And Or Trade In Bio-Tech Stocks?

September 13, 2024

Via Talk Markets

Should You Buy Novavax Stock After This Regulatory Win?

September 13, 2024

Via The Motley Fool

Biotech Breakout: Stocks for Your Watchlist

September 12, 2024

Via MarketBeat

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

September 11, 2024

Via Benzinga

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial

September 11, 2024

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.

September 10, 2024

Via Chartmill

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

September 06, 2024

Via Benzinga

Why Sanofi Stock Was Robustly Healthy Today

September 03, 2024

Via The Motley Fool

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials

September 03, 2024

Via Benzinga

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.